Vistin Pharma ASA (STU:VP4) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:VP4 Vistin Pharma ASA STU:VP4
77 GF Score
Price €1.85
GF Value €2.27
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:VP4
77GF Score
Vistin Pharma ASA STU:VP4
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vistin Pharma ASA (STU:VP4) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of €1.85 is trading 18.7% below its estimated GF Value™ of €2.27. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for STU:VP4:

  • Dividends Received:
  • GF Value™: €2.27 vs. price of €1.85 (18.7% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the STU:VP4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score

Get the complete analysis for STU:VP4

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.85
Price
€2.27
GF Value